Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in Advanced Stage Cholangiocarcinoma
NCT04895046Phase 2Withdrawn
- Start
- Oct 2021
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
01
Overview
A Phase 2 trial of niraparib, dostarlimab in cholangiocarcinoma (CCA). Planned start Oct 2021; status: withdrawn.
02
Drugs
niraparibdostarlimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT04895046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895046.